Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Moderna, Inc. - Common Stock (NQ: MRNA )

32.59 -0.99 (-2.95%)
Streaming Delayed Price Updated: 1:00 PM EST, Feb 27, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Moderna, Inc. - Common Stock

< Previous 1 2
...
18 19 20 21 22 23 24 25 26
...
99 100 Next >
Stocks Fall Ahead Of Key Inflation Data, Gold Defends Record Highs; Bitcoin Stumbles Below $70,000: What's Driving Markets Tuesday?
Stocks edged lower during midday trading on Tuesday as traders maintained a cautious stance in anticipation of the highly awaited Consumer Price Index (CPI) report scheduled for Wednesday, which could... 
Via Benzinga
Topics Economy
Exposures Interest Rates
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Moderna Inc. (NASDAQ: MRNA) Leading the Way in Tuesday Trading Based on Percentage Gain
Via Investor Brand Network
BlackBerry, Nurix Therapeutics, Tesla And Other Big Stocks Moving Higher On Tuesday
U.S. stocks were lower, with the Dow Jones index falling over 200 points on Tuesday. Shares of BlackBerry Limited (NYSE: BB) rose sharply during Tuesday’s session. 
Via Benzinga
Topics Stocks
Exposures US Equities
2 Stocks Down 30% and 27% to Buy and Hold
Look beyond these companies' challenges. 
Via The Motley Fool
Moderna Stock: Buy, Sell, or Hold?
Moderna is more than its COVID-19 vaccine, but risks for investors still exist. 
Via The Motley Fool
Exposures COVID-19
Why Tilray Brands Shares Are Trading Lower By Around 22%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Tilray Brands, Inc. (NASDAQ: TLRY) fell sharply during Tuesday’s session after the company missed third-quarter estimates and said it no longer expects to generate positive adjusted free 
Via Benzinga
Missed Out on Eli Lilly? 2 Healthcare Stocks With Big Catalysts on the Horizon.
These companies are close to launching new products that could supercharge revenue. 
Via The Motley Fool
Bull Market and Beyond: 3 Stocks Just Waiting to Soar
These stocks, a bargain today, are players to hold on to for the long term. 
Via The Motley Fool
Better Recovery Story Buy: Pfizer vs Moderna
Pfizer and Moderna each have slipped about 30% over the past year. 
Via The Motley Fool
A Glimpse Into The Expert Outlook On Moderna Through 5 Analysts
Via Benzinga
3 Healthcare Stocks Short Sellers Are Prescribing for Trouble
The healthcare industry is one of the most potent yet also one of the most competitive. This has short sellers out for blood. 
Via InvestorPlace
Moderna's Vaccines Day 2024: A Glimpse into the Future of Infectious Disease Prevention
Moderna, Inc. (NASDAQ: MRNA) recently hosted its fourth annual Vaccines Day, offering a deep dive into the company's expanding infectious disease vaccines portfolio. 
Via Benzinga
The 3 Most Undervalued Biotech Stocks to Buy in April 2024
The most undervalued biotech stocks to buy in April are intriguing value options with mature biotech plays that boast impressive pipelines. 
Via InvestorPlace
Arbutus Vs. Moderna Patent Dispute Over Covid-19 Vaccine Gets Response From Judge
Delaware Judge favors Arbutus and Genevant Sciences in their patent dispute with Moderna over COVID-19 vaccine technology. 
Via Benzinga
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Moderna Shares Slip Over Covid Vaccine Patent Dispute, But Chart Signals Potential Rebound Ahead
Moderna stock falls 2.32% due to patent infringement suit. However, some investors see this as an opportunity to enter or average out. Golden Cross formation also offers hope for future growth. 
Via Benzinga
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Arbutus Stock Soars 20% As It Heads To Trial With Moderna In Covid Vaccine Patent Claim
Arbutus Biopharma soared more than 20% on Wednesday, April 3, after the company received permission to pursue a claim against Moderna in court. 
Via Benzinga
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Phase 1/2 Interim Data on Moderna’s mRNA-3927, an Investigational mRNA Therapy for Propionic Acidemia, Published in Nature
Via ACCESSWIRE
Pharma's Post-Pandemic Story To Unlock A Cancer-Free Era
Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA) did not only earn billions of dollars from their COVID-19 leading products but also rose to fame for saving the world from an unforeseen pandemic. 
Via Benzinga
Exposures COVID-19
Is Moderna Stock Going to $214? 1 Wall Street Analyst Thinks So.
Moderna, famous for its coronavirus vaccine, is only at the start of a trip skyward, a market professional believes. 
Via The Motley Fool
Exposures COVID-19
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
3 Biotech Stocks That Could Be Multibaggers in the Making: March Edition
Discover these three biotech stocks set for major gains with groundbreaking health solutions. Invest in the future of medicine. 
Via InvestorPlace
Bull Market Buys: 3 Dividend Stocks to Own for the Long Run
Invest in stability, dividends, and growth with these three accomplished real estate operators. 
Via The Motley Fool
Better Cathie Wood Stock: Moderna vs. Intellia
Moderna and Intellia have declined in the double digits over the past year. 
Via The Motley Fool
3 Biotech Stocks to Buy on the Dip: March 2024
Some of the best opportunities can be found in dips in some of the top biotech stocks to buy. In fact, here are three. 
Via InvestorPlace
What's Going On With Moderna Stock Wednesday?
Moderna shares are trading higher Wednesday after the company announced that MRNA-1283 met the primary endpoints in its Phase 3 clinical trial. Additionally, Blackstone Life Sciences announced an... 
Via Benzinga
Moderna Advances Multiple Vaccine Programs to Late-Stage Clinical Trials
Via ACCESSWIRE
Cathie Wood's Ark Invest Continues To Double Down On Moderna, Sells Nvidia Shares
Via Benzinga
Moderna's Next Gen COVID Vaccine Meets Primary Goal In Late-Stage Trial
Moderna announces Phase 3 trial results for mRNA-1283, its next-gen COVID-19 vaccine. A higher immune response was observed compared to mRNA-1273.222. Detailed data will be unveiled at upcoming... 
Via Benzinga
Exposures COVID-19
< Previous 1 2
...
18 19 20 21 22 23 24 25 26
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.